2026-02-26 14:02Financial Data and Key Metrics Changes - Fourth quarter total revenue increased by 17% year-over-year to $127.6 million, with full year revenues growing 15% to $460.2 million [16][19] - Loss from operations improved by 19% for the full year to $229.4 million, and improved by 25% when adjusted for non-cash expenses [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full year revenue growth of 15% year-over-year [6] - XACDURO and NUZYRA contributed significantly to revenue growth, with strong patient demand and market coverage [19] Market Data and Key Metrics Changes - The oncology market is expected to see significant opportunities, with Zoci targeting a total addressable market exceeding $9 billion [11] - The company anticipates a potential accelerated approval submission for Zoci in 2027 and a first global approval in 2028 [10] Company Strategy and Development Direction - The company is focused on building a globally competitive oncology and immunology pipeline, with a clear path toward U.S. approval by 2028 for Zoci [5][11] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted a challenging macro and operating environment but expressed confidence in the execution and preparation for 2026 [6] - The company aims to maintain commercial profitability while investing in high-value global programs [44] Other Important Information - The company ended the quarter with a strong cash position of $790 million, positioning it well for future growth [21] - The focus for 2026 includes maintaining the strength of existing business while preparing for multiple growth opportunities [18] Q&A Session Summary Question: Revenue and expenses outlook for 2026 - Management expects good growth opportunities for VYVGART and steady performance from ZEJULA, with modest investments required for launches [24][25] Question: Zoci's intracranial activity implications - Zoci shows high response rates in patients with untreated brain metastases, which is a significant advantage [28][29] Question: U.S.-China development model - The company leverages efficient development structures in China to accelerate timelines and enhance global trial participation [33][34] Question: KarXT commercialization strategy - The commercial launch of KarXT is planned for the second quarter of 2026, focusing on building physician experience and a commercial team [73] Question: Zoci phase 3 trial design - The company plans to start the first-line study by the end of the year, aiming to spare chemotherapy while assessing durability [85]